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Abstract: Sleep disturbances have been reported to be higher in human immunodeficiency virus 
(HIV)-infected individuals compared to the general population. Despite the consequences of 
poor quality of sleep (QOS), research regarding sleep disturbances in HIV infection is lacking 
and many questions regarding correlates of poor QOS, especially in marginalized populations, 
remain unanswered. We conducted one-on-one qualitative interviews with 14 marginalized 
HIV-infected individuals who reported poor QOS to examine self-reported correlates of sleep 
quality and explore the relationship between QOS and antiretroviral adherence. Findings suggest 
a complex and multidimensional impact of mental health issues, structural factors, and physical 
conditions on QOS of these individuals. Those reporting poor QOS as a barrier to antiretroviral 
adherence reported lower adherence due to falling asleep or feeling too tired to take medications 
in comparison to those who did not express this adherence barrier. These interviews underscore 
the importance of inquiries into a patient’s QOS as an opportunity to discuss topics such as 
adherence, depression, suicidal ideation, and substance use.
Keywords: adherence, HIV/AIDS, interviews, qualitative research, sleep
Introduction
Sleep disturbances have been reported in many studies since early in the human immu-
nodeficiency virus (HIV) epidemic and have been deemed to be higher in HIV-infected 
individuals in comparison to the HIV-seronegative population.1–4 Nearly 73% of people 
living with HIV report sleep disturbances,5 as compared to 10%–35% of the general 
population.6,7 Currently, over 30 years into the HIV epidemic, the exact mechanisms 
of these sleep difficulties are still unknown and understudied, but are hypothesized to 
be correlated with viremia, psychiatric illnesses, illicit drug or alcohol use, or use of 
antiretroviral (ARV) medications.5,8–15
Decreased quality of sleep (QOS) may directly or indirectly, through its associa-
tion with depressive symptoms, result in nonadherence.12,16,17 The personal and public 
health significance of adherence is evident in that small reductions in ARV adherence 
have been associated with loss of virologic control and treatment failure, emergence 
and transmission of drug-resistant virus, and disease progression.18–23 Understanding 
the reasons behind sleep disorders and the impact of poor sleep quality on daily life 
is essential because sleep disturbances have been associated with impaired memory, 
attention, and concentration;24,25 increased psychiatric disorders;26 and higher health 
care utilization.27 In addition, sleep disorders possess an inflammatory component, 
which is thought to be the basis for increased risk of coronary artery disease and 
increased cardiovascular morbidity and mortality.8–10,28–33 In brief, the recognition 
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and timely treatment of poor QOS may result in improved 
ARV adherence and reduced cardiovascular disease, and 
therefore is an important part of the clinical management of 
HIV-infected individuals.
The interaction of ARV nonadherence and hypothesized 
correlates of sleep difficulties, such as psychiatric disorders 
and drug and alcohol use, is particularly pronounced in the 
marginalized HIV-infected population; however, research 
regarding sleep disturbances in this population is lacking. 
Therefore, we conducted a qualitative study to deepen our 
understanding of poor QOS in relation to mental and physi-
cal health aspects of the lives of marginalized HIV-infected 
individuals and to explore ARV adherence in the context 
of poor QOS. In this paper, we report our findings regard-
ing self-reported correlates of poor QOS, the relationship 
between QOS and ARV adherence, and other themes that 
emerged through data analysis.
Methods
Setting
We conducted one-on-one, semistructured, qualitative 
interviews that were nested in the Preparing patients to start 
Antiretroviral Therapy project (PATH, R01MH079700), a 
randomized controlled trial evaluating an intervention to 
enhance information, motivation, and behavioral skills of 
marginalized HIV-infected adults with a CD
4
+ cell count 
,500 cells/mm3 in order to increase the rate of ARV uptake. 
The PATH Project targeted members of the population for 
whom ARVs were strongly advised and who were most 
likely to die from AIDS-related illness or were at increased 
risk of transmitting HIV to others if not engaged in effective 
treatment. Throughout the course of this trial, participants’ 
ARV initiation and adherence was monitored. Participants 
in the PATH project were $18 years of age, had a confirmed 
HIV-positive test, reported knowing their HIV serostatus 
for at least 6 months, had not taken any ARV medications 
for the prior 30 days, had never taken a continuous course 
of ARVs for more than 30 days, had a confirmed CD
4
+ cell 
count ,500 cells/mm3, were able to provide informed consent 
for research, and spoke English. Individuals with cognitive 
impairment, active psychosis, or significant confusion were 
excluded from the project.
Participants
Participants in the qualitative substudy were 14 HIV-infected 
adults from the waitlist control arm of the PATH Project who 
reported poor QOS, as defined by two questions in the Pitts-
burg Sleep Quality Index:34 (1) “During the past month, how 
many hours of actual sleep did you get at night? (This may 
be different than the number of hours you spent in bed),” 
for which participants could enter the number of hours slept 
between 0–24 hours; and (2) “During the past month, how 
would you rate your sleep quality overall?”, where responses 
included (0) very good, (1) fairly good, (2) fairly bad, and 
(3) very bad. We purposefully sampled those who reported 
6 or fewer hours of sleep at night or those reporting “fairly 
bad” or “very bad” sleep quality in the past month. During 
the follow-up period of the PATH Project, several participants 
in the control arm initiated ARVs; therefore, we were able 
to sample among those who had initiated ARVs in order to 
examine the relationship between QOS and ARV adherence, 
as well as those who had not initiated ARVs. Exclusion 
criteria consisted of cognitive impairment or inability to 
participate due to intoxication with alcohol or use of other 
illicit substances at the time of the interview. Participants 
who met the inclusion criteria were contacted by the research 
staff, were consecutively enrolled on a first-come-first-serve 
basis, and received $40 in the form of gift vouchers for 
participation. The University of California, San Francisco 
Committee on Human Research granted approval of this 
project, and participants signed an informed consent form 
prior to initiation of the interview.
Data collection
Data were collected through semistructured, one-time, 1.5- to 
2-hour interviews, during which we focused on narratives of 
the participants’ experiences with poor QOS. All interviews 
were conducted in a private room at the Tenderloin Clinical 
Research Center in San Francisco, California. The first author 
conducted all interviews from February through October of 
2010. The interview guide, which was specifically created for 
this study, consisted of four key sections: (1) demographics 
and social history, consisting of questions about the partici-
pant’s daily schedule, living and family situation, as well 
as disclosure of HIV status; (2) HIV treatment history (as 
applicable), including questions regarding participant’s ARV 
medications, ARV adverse effects, number of doses missed 
in the past week, and reasons for missed doses; (3) sleep 
experience, including questions regarding timeline of sleep 
problems, self-perceived causes of sleep problems, impact 
of sleep difficulties on daily life, methods of dealing with 
sleep problems, experience of dreams, perceived effect of 
ARVs on QOS, and impact of sleep difficulties on ARV 
adherence; and (4) additional questions regarding depression, 
substance use, incarceration, relationship with health care 
providers, and support from family and friends. ARV adher-
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ence was calculated by dividing the total number of doses 
taken per week by the number of expected doses based on 
participants’ ARV regimen. Throughout the process of data 
collection and concurrent analysis, we made minor changes 
to the interview guide in order to probe more deeply into 
topics that our initial analysis indicated were important with 
regard to QOS.
Analysis
We employed an inductive approach to gain a deeper 
understanding of participants’ experiences with and perspec-
tives on factors associated with poor QOS and the impact 
of sleep quality on ARV adherence. This approach entails 
“detailed readings of raw data to derive concepts, themes, 
or a model.”35 Immediately following each interview, the 
first author wrote memos capturing salient points, initial 
thoughts, and impressions of the interview. Additionally, for 
all interviews, the first author summarized the participant’s 
daily schedule, definition of a good night’s sleep, type(s) 
of sleep disturbance, perceived causes of sleep difficulties, 
methods that the participant has tried to deal with poor 
QOS, experiences of dreams, ARV adherence, mental health 
issues, and physical conditions. These analytical memos and 
interview summaries were shared with the second author, 
who listened to the interviews and provided a secondary 
perspective and rendered new or alternative observations. 
Next, the digital audio recordings of the interviews were 
transcribed verbatim and entered into the qualitative data 
analysis software, Transana (Wisconsin Center for Education 
Research, Madison, WI, USA). This software allowed us to 
segment, code, and structure our data for analysis. We used 
an inductive coding process in which the first author read 
and analyzed transcripts, field notes, and memos line by line; 
organized interview contents; developed a set of codes based 
on a priori and emerging themes; and subsequently clustered 
these codes into categories.36 Finally, the first, second, and 
third authors worked together to condense, develop, and refine 
the codes and categories and to organize the data within this 
analytical scheme.
Results
We interviewed 14 HIV-infected individuals with a mean 
age of 44 years who were 79% male at birth, 43% Black, 
and 36% White. At the PATH Project baseline, mean HIV 
viral load was 4.46 log
10
 copies/mL and mean CD
4
+ cell 
count was 222 cells/mm3. All participants reported having 
been homeless, 79% reported having been incarcerated, and 
86% had a high school diploma or greater. Mean number 
of hours of actual sleep per night during the past month 
was 4.6 hours (standard deviation = 1.7), and the majority 
of participants rated their overall QOS in the past month as 
“fairly bad.”
When asked to define good sleep quality, participants’ 
responses included uninterrupted sleep for 8 hours, feeling 
rested and energized upon awakening, feeling relaxed and 
without fear or worry during the night, and not experiencing 
repeated awakenings due to physical issues such as muscle 
spasms or diarrhea. Many participants reported not having 
given much thought to the root of their sleep problems, not 
having fully considered the potential reasons for their sleep 
difficulty, and infrequently discussing these issues with 
their health care providers. Many stated that their reason 
for rarely discussing their sleep with their physician was 
the presence of other pressing health issues (such as can-
cer, trauma, or homelessness), the need to stay alert in the 
street (if homeless) and therefore not wanting to fall into 
deep sleep, the presumed quick-to-prescribe nature of this 
interaction, and the participants’ aversion to taking even 
more medications.
All participants reported consequences of their poor 
QOS, such as difficulty concentrating, frequently falling 
asleep during the day, memory loss, constant fatigue, and 
needing to change their daily routine due to exhaustion. 
Participants reported experimenting with a variety of tech-
niques to help improve their sleep. These methods included 
the use of a variety of substances, including alcohol, 
cigarettes, marijuana, other street drugs (such as crack and 
cocaine), over-the-counter medications (such as diphen-
hydramine), and prescription medications (such as zolpidem, 
trazodone, hydrocodone, mirtazapine, quetiapine, and clon-
azepam), as well as nonpharmacologic methods such as sleep 
deprivation, meditation, reading, creative writing, watching 
television, exercising and exertion, and sleeping in a safe 
indoor space, such as a hospital emergency room.
We discuss salient themes that emerged through our 
data analysis. While acknowledging considerable overlap 
and interplay among them, we group these themes into the 
following categories: ARV adherence, mental health issues, 
structural factors, and physical conditions.
Sleep and ARV adherence
Since enrollment in the PATH Project, 71% (n = 10) 
of participants had initiated ARVs at the time of their 
respective interviews; 50% were taking a protease inhib-
itor-based regimen, 14% had started an efavirenz-based 
regimen, and 7% were on an integrase inhibitor-based 
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regimen. Among these ten participants, self-reported ARV 
adherence in the previous week was approximately 95% 
(range = 73%–100%).
The topic of ARV nonadherence due to falling asleep, 
being too tired to take medications, or lack of concentra-
tion due to fatigue was brought up by participants in five 
interviews. Adherence among these five individuals was 
90% (range = 73%–97%) and falling asleep or lack of sleep 
accounted for approximately one to four missed doses per 
week, which represented 50%–100% of their total weekly 
missed doses. These doses were predominantly in the 
evening.
Participant: I get tired real easy a lot. I don’t sleep that much 
even though I’m always tired.
Interviewer: For the past week when you [said that you] 
missed three or four doses, how many of that do you think 
would have been somehow related to your sleep?
Participant: More than half; at least more than half. 
[31-year-old Latino male on ARVs]
Sleep and mental health issues
Among the participants, the mean Center for Epidemiologic 
Studies Depression Scale score was 33 (indicative of major 
depression). All participants stated that they felt depressed or 
had been diagnosed with depression. All had been prescribed 
antidepressant medications and referred for mental health 
services during the course of their clinical care, but most of 
those adhering to their antidepressant medications and receiv-
ing mental health services indicated that their QOS had not 
significantly improved. Depression influenced participants’ 
QOS by impacting their ability to fall asleep and stay asleep, 
experience of dreams, initiative to get out of bed in the morn-
ing, and need to take frequent naps. Participants directly 
attributed their poor QOS to struggling with depression, as 
articulated by a 45-year-old Black male on ARVs:
[…]in my depression I think what keeps me up a lot is that 
it has a tendency to make my mind wonder “what if ” […] 
I can lay in the bed and not go to sleep, I just don’t want 
to get up […] sometimes I’ve laid in the bed on a weekend 
just two or three days and just lay there and not sleep. I’m 
just there […] I don’t want to do anything […] I don’t want 
to cry, I don’t want to care […] I get to the point where I 
don’t think it’s just worth anything.
Although most participants did not attribute changes in 
their sleep quality to HIV seroconversion, many discussed the 
mental stress and worry after testing positive, the anxiety of 
living with HIV, and the fear of infecting others as severely 
impacting their QOS. As expressed by a 55-year-old Black 
female not on ARVs:
Fear of dying and having HIV, just a fear [of] having 
HIV […] you need to think about being ashamed. And, 
sleeping, it’s got a lot to do with your resting inside, men-
tally. If you can’t rest inside mentally, you’re not sleeping 
nowhere, no matter where you go.
Or in the words of a 35-year-old White male on ARVs:
When I’m at home at night in the darkness with myself, 
that’s when I can’t fake anything and that’s when all these 
things come out, and that’s when I would [think] “What if 
no one ever loves me, what if I can never find somebody to 
love this infected person, what if I die and my parents have 
to take care of me.” All these things that I shouldn’t have to 
think about […] I have to think about every night[…]
A recurring and unsolicited theme that emerged from 
these interviews was suicidal ideation. Six of the 14 partici-
pants reported having attempted suicide or having frequent 
thoughts of suicide. All stated that they would not hurt 
themselves but had thought about it in detail or had failed 
attempts in the past.
In addition to the high prevalence of depression, 
all participants indicated past or current substance use. 
 Substances used included alcohol, crystal meth, crack, 
cocaine, ecstasy, heroin, marijuana, and methadone. All 
participants mentioned substance use as a direct reason for 
their inability to sleep or erratic sleep patterns, although 
marijuana was considered a method to assist in initiating 
sleep and was used successfully by several participants. 
Several individuals discussed the impact of these substances 
in terms of changing one’s sleep patterns, experiencing vivid 
and intense dreams, having “fake sleep” (referring to the 
participant constantly feeling somnolent with heroin use but 
being unable to attain deep sleep), not feeling rested, and 
staying up all night or for several days and then sleeping 
for numerous days. A 55-year-old Black female on ARVs 
explained how the need to attend to her heroin addiction 
did not permit her time to sleep:
[Heroin] affected [my sleep] a lot because I couldn’t sleep. 
I didn’t have time to sleep. I had to think about how I’m getting 
the next one […] especially when you’re a heroin addict and you 
don’t have the money, you don’t have time to sleep, you have 
no time to sleep. You have no time for anything except plan-
ning for how you’re going to get that next drug. That’s it!
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A 35-year-old White male on ARVs was clear about the 
impact of substance use on his sleep quality: “The crystal 
meth use where I would be up for three or four days […] and 
then crash, that definitely messed up my sleep schedule […] 
I don’t like to sleep as much anymore.”
Eight of the participants stated that they frequently had 
nightmares. They stated that, at times, the anxiety from the 
possibility of having nightmares would prevent them from 
falling asleep, or the fear that they had experienced during 
a nightmare would frequently wake them up. A 45-year-
old Black male on ARVs referred to his dreams as “reality 
nightmares” because “even though you’re asleep they are so 
real, you actually wake up tired from it.”
One [dream] is from childhood […] the giant Muppets 
are chasing me down this long hall and I can never get 
away from them and it’s the most terrifying thing in the 
world […] And then there’s several scenarios that when 
I was with my partner that beat me […] and it feels like when 
I wake up that it just happened, especially the beating dreams 
and the chasing dreams. It feels like I’m actually running 
from the people or they’re trying to hurt me. [35-year-old 
White male on ARVs]
A 31-year-old Latino male on ARVs associated his night-
mares with the HIV virus, stating: “It’s a parasite invading 
my body. It can’t be good. My mind has got to think about 
it. Subconsciously it’s gotta wonder about it. The thing is 
attacking me and attacking my immune system.”
A well-known and commonly reported adverse effect of 
efavirenz is vivid dreams. Two participants were taking an 
efavirenz-based ARV regimen at the time of the interview, 
and another participant had previously taken an efavirenz-
based ARV regimen. All three recalled vivid dreams of using 
illicit substances, feeling the guilt associated with relapsing, 
and contemplating actually relapsing.
I can visualize the pipe, smoking it, the crazy up feeling you 
get, and then, I’ll wake up and I’ll be, well, I could get on 
the Internet [to obtain illicit drugs]. I could find somebody 
[a dealer] […] I don’t have any of those phone numbers 
anymore, but I’ve learned, living in this city, that there are 
ways. [35-year-old White male on ARVs]
A 41-year-old Black male on ARVs detailed similar 
experiences:
There were dreams […] where I had used and thought that 
I had relapsed in real life, and [I] went through all those 
emotions, and I woke up just […] shaking or like, oh my 
God, it’s all over, I relapsed. [I could see] everything […] 
up to the point of going to get it […] and putting the crack 
on the pipe and smoking it, and all the feelings […] the 
anticipation, the fear, the anxiety, the fact that I was actually 
doing this and it felt so real […] I was like, oh my God! 
What is my counselor going to say? What is my case worker 
going to say? They’re going to [say] […] you can’t do this, 
what are you doing? […] and I’m saying, I can’t do this, 
but I went ahead and did it and then I was devastated […] 
It’s like, it’s all bad, and then it’s like but, you did it so you 
might as well go on and keep doing it.
Disturbing nightmares were also discussed in connec-
tion with another recurring and unsolicited mental health 
theme, the issue of coping with childhood abuse or rape. Six 
individuals recounted childhood abuse from family members 
or friends and the impact of these incidents on their current 
lives (such as the repercussions of running away from home 
at a young age or engaging in sex work).
I had a recurring abuse nightmare with my uncle. To the 
point to where I literally would like die; I [would] have to 
keep my nails cut because I literally gashed into my leg. 
[45-year-old Black male on ARVs]
Sleep and structural factors
All participants reported having been homeless, and two were 
homeless at the time of the interview. These two participants 
stated that they took very short naps at night and tried to be 
alert for security reasons. They stated that they woke up 
frequently due to fear of being assaulted while asleep or 
robbed for their pocket money. In the words of a 55-year-
old Black female not on ARVs: “When you sleep outside, 
you don’t sleep like a normal person sleeps. You have to be 
careful with yourself.”
A 49-year-old American-Indian male on ARVs expressed 
similar safety concerns: “[They can] beat me to death with a 
crowbar while I sleep. Hit me in the head […] or throw gas 
on me, light me on fire because I’m homeless […] It’s easy 
to walk up on somebody when they’re sleeping and just kill 
them and they can walk off and get away with it.”
One 55-year-old Black female on ARVs who had been 
homeless 2 years prior to the interview stated that she was 
still unable to sleep well despite living in a comfortable and 
safe environment because of the changes in her sleep pat-
tern while homeless: “That’s probably why I wake up like I 
do now. I was so busy having to be on watch […] You never 
know what’s going to happen, so you definitely can’t sleep 
good there.”
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Likewise, two individuals who lived in single occupancy 
rooms also commented on their inability to sleep due to the 
intolerable noise level of other occupants and their mistrust 
of the security of their rooms. One 42-year-old Black male 
on ARVs stated:
I don’t feel comfortable there. I can’t sleep for two or three 
days, I’m going through a lot of mental stress in that build-
ing […] I lock the door and I’d be tired, I still don’t sleep 
well, because […] people are cruising around my door […] 
But, when I do sleep well, I sleep well because I am tired 
to where it doesn’t bother me.
The other, a 41-year-old Black male on ARVs, voiced 
similar worries:
[T]hose are the people that I’m concerned about because they 
know […] that they could get in [to my room] […] because 
this one guy told me once “this dude […] wouldn’t give me 
something and so, he didn’t know that I came in his room 
and sat by his bedside, and I could’ve done anything I wanted 
to do […]” So, it […] planted in the back of my mind that, 
somebody could do that at my house […] Some nights I 
would lock the window if I was really tripping that hard[…]
Finally, eleven of the participants had a history of incar-
ceration. Of these, three distinctly described their experiences 
in prison as contributing to their sleep difficulties. These 
experiences included the requirement to wake up extremely 
early to eat breakfast according to the prison schedule, receive 
medications by standing in “pill-call,” and arrive at various 
appointments.
They had a whole different schedule in jail […] So, dealing 
with those stresses it was like that set a pattern for me for 
those six and a half months […] getting up at 3:30 in the 
morning for breakfast, or if you had an appointment outside 
they would wake you up that early, and then they had pill-
call like an hour later […] Maybe that’s still sticking with 
me. [41-year-old Black male on ARVs]
In addition, participants described the sleep-disturbing 
effects of the trauma associated with witnessing and expe-
riencing violence in correctional facilities. A 49-year-old 
American-Indian male on ARVs acknowledged using diaz-
epam, clonazepam, mirtazepine, and quetiapine to reduce his 
incarceration-related anxiety and to help him sleep.
I get anxiety attacks, panic attacks […] Killing, I’ve seen a 
lot of killing in prison […] But, when you’re in there you 
learn how to survive too. You learn the ropes. Step over bod-
ies, you leave them there, you don’t say nothing to nobody, 
you just step over them, go do what you’re supposed to do.
Sleep and physical conditions
Among the participants, ten stated that physical issues related 
to ARV medication adverse effects, HIV infection, or sleep-
ing conditions were resulting in poor QOS. These physical 
issues consisted of flatulence, diarrhea, cramps and spasms 
in extremities, back and neck pain, toothache, headache, pain 
associated with prior trauma, asthma and breathing difficulties, 
and cancer pain. Most participants noted their need to take 
substantial quantities of pain medications, including over-the-
counter, prescription, and illicit drugs, for pain relief and sleep.
In addition, seven of the participants discussed the issue 
of excessive sweating while sleeping, waking up from the dis-
comfort, and being unable to fall back asleep. A 31-year-old 
White male on ARVs described it as such: “Night sweats: 
wake up because you’re so soaking wet from sweat. Then 
you can’t go back to sleep because you’re freezing […] I 
have night sweats all the time […] You have to change your 
clothes.”
Individuals discussed using fans at night, placing towels 
on their bed and pillow as precaution, not sleeping due to the 
fear of waking up drenched, and not wanting to be intimate 
due to feeling self-conscious of their excessive sweating.
Not too many people are going to sleep through putting them-
selves in a river of sweat […] I’ve been in several relationships 
in my life […] but even the ones that weren’t partners and 
we laid together in the bed, that was an issue. Because some 
people […] wanted to cuddle, they wanted to be close, and 
I’m like, no, because I’m going to sweat or, you know, it gets 
too hot[…]. [41-year-old Black male on ARVs]
Discussion
These qualitative interviews suggest a complex and mul-
tidimensional impact of mental health issues (such as 
depression, anxiety, suicidal ideation, substance use, child-
hood abuse, and dreams), structural factors (such as living 
situations and incarceration), and physical conditions (such 
as pain and night sweats) on the sleep quality of marginal-
ized HIV-infected individuals. In general, participants did 
not associate changes in their QOS with initiation of ARV 
medications and had not related any deterioration in their 
sleep quality to seroconversion; however, there were reports 
of physical issues due to ARV adverse effects and HIV 
infection and psychological issues due to fear and anxiety 
surrounding their HIV status. Those reporting nonadher-
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ence due to falling asleep before dosing time or feeling too 
tired to take medications also reported having lower ARV 
adherence.
Despite the significant impact of sleep quality on their 
lives, most participants had not discussed this issue with 
their providers. This omission may have been due to the 
overwhelming number of psychosocial issues that may have 
taken precedence (ie, passive reluctance to discuss QOS 
due to competing priorities) or a quick-to-prescribe view on 
the medical establishment, which would result in the need for 
the participant to take more medications, potentially experi-
ence more adverse effects, or be less alert if living on the 
street. Correspondingly, it was evident that many participants 
were uninformed of effective approaches to enhance sleep 
given their self-reported methods, such as alcohol, cigarettes, 
long-term use of antihistamines, watching television, and 
substance use, which may be ineffective or can exacerbate 
insomnia and result in further sleep disruption. A few noted 
improvements in QOS with exercise and exertion, reading, 
and creative writing. Of those taking prescription medica-
tions for sleep, depression, and anxiety, few indicated major 
improvements in their QOS.
All participants reported feeling depressed or being diag-
nosed with depression. The relationship between depression 
and QOS is closely intertwined, as those with depressive 
disorders often report high rates of poor QOS,37,38 and vice 
versa.39–42 Due to this close correlation, there has been much 
research and debate regarding the chronology between sleep 
disorders and depression.43–46 Poor QOS in depressed indi-
viduals can interfere with daytime functioning and result in a 
reduction in adherence to treatment.16 In a study of the rela-
tionship between sleep disturbance, depressive symptoms, 
and ARV adherence in HIV-infected women, sleep quality 
was negatively associated with adherence in women who 
were also depressed, suggesting that depression is a possible 
mediator in the relationship between QOS and adherence.17
A frequently recurring and unsolicited theme that was 
recounted by nearly half of our sample was suicidal ideation, 
which may have been related to depression and therefore 
associated with poor QOS.12 In the Swiss National Cohort, 
Keiser and colleagues demonstrated a reduction in suicides 
when comparing the period prior to ARV therapy to the late 
ARV therapy era;47 however, the suicide rates remain more 
than three times higher in the HIV-infected population com-
pared to the general public.
Few individuals in our study related their sleep difficul-
ties to adverse effects from their ARV medication. A clear 
association between the use ARVs and changes in QOS has 
not been demonstrated.5,12,13,48,49 Efavirenz, an HIV non-
nucleoside reverse transcriptase inhibitor, has been  associated 
with central nervous system side effects. The likelihood 
of this adverse effect has been reported to be as high as 
22%–24%,50,51 and vivid dreams, difficulties falling asleep, 
and night awakenings are frequently reported.14,15,52 In two 
studies,12,49 despite the fact that the use of efavirenz resulted 
in changes in stages or report of vivid dreams, participants 
remained satisfied with their QOS or did not report changes 
in sleep patterns. However, two of our study participants who 
were former drug users and had taken efavirenz discussed 
increased awakening due to vivid dreams and experiencing 
distress due to dreams regarding drug relapse.
The relationship between QOS and childhood abuse, 
posttraumatic stress from suffering or witnessing violence, 
depression, HIV, homelessness, incarceration, substance 
use, and physical issues have been described in prior 
research;11,12,53–60 however, these issues have often not been 
studied in conjunction with each other and have infrequently 
been examined in a marginalized HIV-infected population. 
Results of our qualitative research extend findings from 
these studies, examine various self-reported correlates 
of sleep quality simultaneously, describe the association 
between QOS and ARV adherence, and reveal the lack of 
disclosure but willingness to speak about sleep problems to 
health care providers and the level of information regarding 
sleep-enhancing methods in a marginalized HIV-infected 
population.
A limitation of our exploratory study is that the pur-
poseful sampling of our patient population was restricted to 
individuals with poor QOS in the waitlist control arm of the 
PATH Project; therefore, our results may not be generalizable 
to other populations. However, the intention of this study was 
to generate a preliminary account of QOS, ARV adherence, 
and other correlates in HIV-infected individuals. The assess-
ment of the generalizability of our findings and their utiliza-
tion in quantitative studies will be the focus of our future 
research. Additionally, we relied on a self-reported medica-
tion adherence measure which tends to be an overestimate 
of true adherence; therefore, future research should estimate 
adherence using multiple methods, such as pharmacy refill 
records or electronic drug monitoring.
From a research standpoint, forthcoming QOS studies in 
HIV-infected individuals should include questions regarding 
ARV adherence, mental health issues (such as depression, 
anxiety, suicidal ideation, substance use, childhood abuse, 
trauma, and dreams), structural factors (such as living situ-
ations and incarceration), physical conditions (such as pain 
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and night sweats), and disclosure of sleep difficulties to health 
care providers. Additionally, future research should examine 
the efficacy of patient-tailored interventions, using methods 
such as education and counseling on sleep hygiene, cognitive 
behavioral therapy, and pharmacologic approaches for the 
treatment of poor QOS. Studies should determine changes in 
sleep quality in individuals newly diagnosed with HIV and if 
the recognition and timely treatment of sleep difficulties in 
those who report ARV nonadherence due to sleep problems 
can result in improved adherence. Finally, due to insufficient 
research regarding QOS in HIV-infected individuals, we 
relied on several dated references. Due to the prevalence of 
sleep difficulties among people living with HIV, we believe 
that emphasis should be placed on the execution of well-
designed research in this area.
Findings from these interviews suggest that QOS may 
be among various factors that can influence ARV adherence. 
Despite the fact that few participants had mentioned this issue 
to their provider, they were willing to openly discuss their 
sleep difficulties, their fears and anxieties surrounding sleep, 
and other sensitive topics such as suicidal ideation, childhood 
abuse, and substance use. Therefore, from a clinical perspec-
tive, inquiries into a patient’s QOS can serve as a gateway to 
discussing these sensitive topics, because QOS questions are 
less emotionally charged, more socially acceptable, and can 
be conducted using a few questions. QOS can be assessed by 
asking questions about the patient’s bedtime, the time they 
raise, number of times they wake up in the middle of the night 
and the approximate duration of these awakenings, difficulty 
falling asleep or staying asleep, night terrors or night sweats, 
feeling fatigued in the morning, and struggling to stay awake 
during the day. Findings regarding poor sleep quality should 
prompt an assessment of ARV adherence and depression, 
potentially an evaluation of suicidal ideation and substance 
use, sleep hygiene counseling, and possible referral to sleep 
medicine specialists.
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